Discontinued — last reported Q3 '25
Investing
Investment Proceeds
Royalty Pharma Investment Proceeds increased by 50.0% to $4.32M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 65.7%, from $12.59M to $4.32M. Over 4 years (FY 2021 to FY 2025), Investment Proceeds shows a downward trend with a -23.7% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2020
Last reportedQ3 2025
How to read this metric
An increase suggests the liquidation of assets to raise cash, while a decrease indicates a strategy of holding investments to maturity or reinvesting.
Detailed definition
This metric represents the cash inflows from the sale or maturity of marketable securities and other financial investmen...
Peer comparison
Often mirrors the purchase of investments; peers use these inflows to manage working capital fluctuations or fund strategic initiatives.
Metric ID:
proceeds_from_investmentsHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.63M | $15.63M | $15.63M | $15.63M | $15.63M | $15.63M | $495.17M | $0.00 | $0.00 | $0.00 | $1.44M | $1.44M | $2.88M | $2.88M | $12.59M | $12.59M | $2.88M | $2.88M | $2.88M | $4.32M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | >999% | -100.0% | — | — | — | +0.0% | +100.0% | +0.0% | +337.0% | +0.0% | -77.1% | +0.0% | +0.0% | +50.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | >999% | -100.0% | -100.0% | -100.0% | -99.7% | — | — | — | +774.0% | +774.0% | +0.0% | +0.0% | -77.1% | -65.7% |
Range$0.00 – $495.17M
CAGR-23.7%
Avg YoY Growth+313.4%
Median YoY Growth+0.0%
Current Streak3 quarters growth
Investment Proceeds at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's investment proceeds?
- Royalty Pharma (RPRX) reported investment proceeds of $4.32M in Q1 2026.
- How has Royalty Pharma's investment proceeds changed year-over-year?
- Royalty Pharma's investment proceeds decreased by 65.7% year-over-year, from $12.59M to $4.32M.
- What is the long-term trend for Royalty Pharma's investment proceeds?
- Over 4 years (2021 to 2025), Royalty Pharma's investment proceeds has grown at a -23.7% compound annual growth rate (CAGR), from $62.50M to $21.23M.
- What does investment proceeds mean?
- Cash received from selling or maturing financial investments.